Insider Buying: STAAR Surgical (NASDAQ:STAA) Major Shareholder Purchases 108,720 Shares of Stock

STAAR Surgical (NASDAQ:STAA) major shareholder Broadwood Partners, L.P. acquired 108,720 shares of the business’s stock in a transaction that occurred on Thursday, March 20th. The shares were acquired at an average cost of $17.96 per share, with a total value of $1,952,611.20. Following the transaction, the insider now directly owns 12,182,995 shares in the company, valued at $218,806,590.20. The trade was a 0.90 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. Large shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.

Broadwood Partners, L.P. also recently made the following trade(s):

• On Tuesday, March 18th, Broadwood Partners, L.P. purchased 93,124 shares of STAAR Surgical stock. The stock was acquired at an average cost of $17.54 per share, for a total transaction of $1,633,394.96.
• On Monday, March 3rd, Broadwood Partners, L.P. acquired 249,503 shares of STAAR Surgical stock. The stock was bought at an average price of $16.64 per share, for a total transaction of $4,151,729.92.
• On Thursday, February 27th, Broadwood Partners, L.P. bought 259,316 shares of STAAR Surgical stock. The shares were bought at an average price of $17.05 per share, with a total value of $4,421,337.80.
• On Friday, February 14th, Broadwood Partners, L.P. purchased 36,532 shares of STAAR Surgical stock. The stock was bought at an average price of $15.49 per share, for a total transaction of $565,880.68.
• On Wednesday, February 12th, Broadwood Partners, L.P. bought 259,616 shares of STAAR Surgical stock. The stock was bought at an average price of $14.96 per share, with a total value of $3,883,855.36.
• On Thursday, January 16th, Broadwood Partners, L.P. purchased 8,221 shares of STAAR Surgical stock. The shares were purchased at an average price of $21.50 per share, for a total transaction of $176,751.50.
• On Tuesday, January 14th, Broadwood Partners, L.P. acquired 21,155 shares of STAAR Surgical stock. The stock was purchased at an average price of $21.46 per share, with a total value of $453,986.30.

STAAR Surgical Trading Down 1.1 %

NASDAQ:STAA opened at $17.72 on Friday. The stock has a market capitalization of $874.04 million, a P/E ratio of -43.22 and a beta of 0.66. STAAR Surgical has a 1 year low of $13.50 and a 1 year high of $52.68. The firm has a 50 day moving average of $19.87 and a 200-day moving average of $25.66.

Hedge Funds Weigh In On STAAR Surgical

Several institutional investors have recently bought and sold shares of STAA. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in shares of STAAR Surgical by 13.4% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 110,506 shares of the medical instruments supplier’s stock worth $2,684,000 after purchasing an additional 13,075 shares during the last quarter. Voloridge Investment Management LLC lifted its position in STAAR Surgical by 9.4% during the 4th quarter. Voloridge Investment Management LLC now owns 296,256 shares of the medical instruments supplier’s stock worth $7,196,000 after buying an additional 25,350 shares in the last quarter. Squarepoint Ops LLC grew its holdings in STAAR Surgical by 81.3% during the 4th quarter. Squarepoint Ops LLC now owns 117,074 shares of the medical instruments supplier’s stock worth $2,844,000 after acquiring an additional 52,488 shares during the last quarter. Sherbrooke Park Advisers LLC acquired a new stake in STAAR Surgical in the 4th quarter valued at about $502,000. Finally, Raiffeisen Bank International AG bought a new position in shares of STAAR Surgical in the fourth quarter worth about $1,926,000. Institutional investors own 96.70% of the company’s stock.

Analysts Set New Price Targets

Several research analysts recently commented on STAA shares. BTIG Research cut STAAR Surgical from a “buy” rating to a “neutral” rating in a research report on Wednesday, February 12th. Mizuho lowered shares of STAAR Surgical from an “outperform” rating to a “neutral” rating and decreased their target price for the company from $45.00 to $17.00 in a research report on Wednesday, February 12th. Stifel Nicolaus dropped their price target on shares of STAAR Surgical from $38.00 to $20.00 and set a “buy” rating for the company in a research report on Wednesday, February 12th. William Blair downgraded STAAR Surgical from an “outperform” rating to a “market perform” rating in a report on Wednesday, February 12th. Finally, Stephens reissued an “equal weight” rating and issued a $17.00 target price on shares of STAAR Surgical in a report on Tuesday, March 18th. Two research analysts have rated the stock with a sell rating, eight have assigned a hold rating and one has assigned a buy rating to the company’s stock. According to data from MarketBeat.com, STAAR Surgical currently has a consensus rating of “Hold” and a consensus target price of $25.29.

STAAR Surgical Company Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.